Stifel analyst Alex Thompson raised the firm’s price target on Morphic (MORF) to $57 from $30 and keeps a Hold rating on the shares. The firm is updating its model to reflect the recently-announced Eli Lilly (LLY) acquisition for $57 per share, telling investors that it views the likelihood of deal close as high.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF: